Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action

Journal of Theoretical Biology

Volumn 265, Issue 4, 2010, Pages 704-717

  Khalili, Samira ^a   Monaco, James M ^b   Armaou, Antonios ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

HIV; Mathematical modeling; NRTI; Reverse transcription; Stochastic modeling

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE; NUCLEOSIDE;

CONCENTRATION (COMPOSITION); DISEASE TREATMENT; DRUG; HUMAN IMMUNODEFICIENCY VIRUS; MODELING; MUTATION; SENSITIVITY ANALYSIS; STOCHASTICITY;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; REVERSE TRANSCRIPTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STOCHASTIC MODEL; VIRUS ATTACHMENT; ALGORITHM; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; GENETICS; HALF LIFE TIME; HUMAN; IC50; INTRACELLULAR SPACE; KINETICS; METABOLISM; MUTATION; STATISTICS; TIME; TREATMENT OUTCOME;

ALGORITHMS; DRUG RESISTANCE, VIRAL; HALF-LIFE; HIV REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SPACE; KINETICS; MODELS, BIOLOGICAL; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTION; STOCHASTIC PROCESSES; TIME FACTORS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954469664     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.05.006     Document Type: Article

References (50)

1. Arion D., Kaushik N. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase'. Biochemistry 1998, 37:15908-15917.
2. Arion D., Parniak M.A. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resistance Updates 1999, 2:91-95.
3. Arkin A., Ross J. Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics 1998, 149:1633-1648.
4. Balzarini J., Herdewijn P. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, 2 potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 1989, 264:6127-6133.
5. Bartlett J.G. Medical Management of HIV Infection 2004, Johns Hopkins Medicine Health Publishing Business Group, Johns Hopkins University Press, Baltimore, MD.
6. Becher F., Landman R. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004, 18:181-187.
7. Becher F., Pruvost A. A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J. Mass Spectrosc. 2003, 38:879-890.
8. Brunton L.L., et al. The Pharmacological Basis of Therapeutics 2006, McGraw Hill.
9. Charneau P., Alizon M., Clavel F. A 2nd origin of DNA plus-strand synthesis is required for optimal human-immunodeficiency-virus replication. J. Virol. 1992, 66:2814-2820.
10. Cherrington J.M. Kinetic interaction of the diphosphate of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma. Antiviral Chem. Chemother. 1995, 6:217-221.
11. Chi J.D., Jayewardene A. A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS. AIDS 2001, 26:829-836.
12. Culshaw R.V., et al. Optimal HIV treatment by maximizing immune response. J. Math. Biol. 2004, 48:545-562.
13. DeJong M.D., et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. PNAS 1996, 93(11):5501-5506.
14. Ding A.A., Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math. Biosci. 1999, 160(1):63-82.
15. Fletcher C.V., Acosta E.P. Concentration-controlled zidovudine therapy. Clin. Pharmacol. Ther. 1998, 64:331-338.
16. Gallois-Montbrun S., Faraj A. Broad specificity of human phosphoglycerate kinase for antiviral nucleoside analogs. Biochem. Pharm. 2004, 68:1749-1756.
17. Gao W.Y., Shirasaka T. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 1993, 91:2326-2333.
18. Gillespie D.T. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. J. Comput. Phys. 1976, 22:403-434.
19. Gotte M., Li X.G. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys. 1999, 199-210.
20. Greco W.R., Bravo G. The search for synergy-a critical review from a response-surface perspective. Pharmacol. Rev. 1995, 47:331-385.
21. Hawkins T., Veikley W. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. JAIDS 2005, 39:406-411.
22. Hsieh J.C., Zinnen S. Kinetic mechanism of the DNA-dependent DNA-polymerase-activity of human-immunodeficiency-virus reverse transcriptase. J. Biol. Chem. 1993, 268:24607-24613.
23. Huang Y.X., Rosenkranz S.L. Modeling HIV-1 dynamics and antiviral response with consideration of time-varying drug exposure, adherence, and phenotypic sensitivity. Math. Biosci. 2003, 184:165-186.
24. Isel C., Ehresmann C. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J. Biol. Chem. 2001, 276:48725-48732.
25. Joly M., Pinto J.M. Role of mathematical modeling on the optimal control of HIV-1 pathogenesis. AICHE J. 2006, 52:856-884.
26. Kakuda T.N., Anderson P.L. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004, 18:2442-2444.
27. Kati W.M., Johnson K.A. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 1992, 267:25988-25997.
28. Khalili S., Armaou A. An extracellular stochastic model of early HIV infection and the formulation of optimal treatment policy. Chem. Eng. Sci. 2008, 63:4361-4372.
29. Khalili S., Armaou A. Sensitivity analysis of HIV infection response to treatment via stochastic modeling. Chem. Eng. Sci. 2008, 63:1330-1341.
30. Kirschner D., et al. Optimal control of the chemotherapy of HIV. J. Math. Biol. 1997, 35:775-792.
31. LANL & NIH. HIV sequence database 〈http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html〉.
32. Meyer P.R., Matsuura S.E. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. PNAS 1998, 95:13471-13476.
33. Meyer P.R., Matsuura S.E. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 1999, 4:35-43.
34. Meyer P.R., Smith A.J. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J. Biol. Chem. 2004, 279:45389-45398.
35. Meyerhans A., Vartanian J.P. Restriction and enhancement of human-immunodeficiency-virus type-1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 1994, 68:535-540.
36. Miller M.D., Lamy P.D. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol. Pharm. 1998, 54:291-297.
37. Naeger L.K., Margot N.A. Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine. Nucleosides, Nucleotides Nucleic Acids 2001, 20:635-639.
38. Nowak M.A., et al. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 1997, 184(2):205-216.
39. Perelson A.S., Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 1999, 41(1):3-44.
40. Ray A.S., Myrick F.F. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antiviral Ther. 2005, 10:451-457.
41. Salis H., Kaznessis Y. Accurate hybrid stochastic simulation of a system of coupled chemical or biochemical reactions. J. Chem. Phys. 2005, 122:54103-54113.
42. Sarafianos S.G., Hughes S.H. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. Int. J. Biochem. Cell Biol. 2004, 36:1706-1715.
43. Sluis-Cremer N., Arion D. Mutational analysis of Lys(65) of HIV-1 reverse transcriptase. Biochem. J. 2000, 348:77-82.
44. Snedecor S.J. Comparison of three kinetic models of HIV-1 infection: implications for optimization of treatment. J. Theor. Biol. 2003, 221:519-541.
45. Solas C.Y., Li F. Intracellular nucleotides of 2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 1998, 42:2989-2995.
46. Thomas D.C., Voronin Y.A. Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis. J. Virol. 2007, 81:4798-4807.
47. Wahl L.M., Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. London Ser. B Biol. Sci. 2003, 267:835-843.
48. Walensky R., et al. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. JAIDS 2002, 31:27-37.
49. Zheng Y.H., Lovsin N. Newly identified host factors modulate HIV replication. Immuno. Lett. 2005, 97:225-234.
50. Zurakowski R., Teel A.R. A model predictive control based scheduling method for HIV therapy. J. Theor. Biol. 2006, 238:368-382.